Results: 3 RCTs contained data regarding mRSS at week 12 of treatment with Rituximab. The estimated SMD was -1.07 (95% CI -1.68, -0.535 [p <0.001]) with a non-significant P value in the Egger Test (P = 0.703) and non-significant heterogeneity through I2 (I2 = 0.00%). 9 studies contained data regarding mRSS at week 24 of treatment with Rituximab. The estimated SMD was -1.743 (CI95% -2.622, -0.864 [p <0.001], see image below) with a non-significant P value in the Egger Test (P = 0.072) and significant heterogeneity through I2 (I2 = 86.6%). Meta-regression analysis could not be performed to assess such heterogeneity, due to the lack of comparable data.

8 RCTs contained data regarding mRSS at week 48 of Rituximab treatment. The estimated SMD was -1.327 (CI95% -2.018, -0.636 [p <0.001]) with a significant P value in the Egger Test (P = 0.018), estimating that there may be publication bias in the studies analyzed and significant heterogeneity by I2 (I2 = 85.2%). Meta-regression analysis could not be performed to assess such heterogeneity, due to the lack of comparable data.

Conclusion: Our meta-analysis shows that Rituximab treatment in patients affected with systemic sclerosis shows efficacy in the treatment of cutaneous fibrosis measured by the mRSS, turning this molecule into a potential drug to add to the therapeutic armamentarium of systemic sclerosis. However, more studies are necessary to try to elucidate whether this change is powerful enough to become the new gold standard for the treatment of systemic sclerosis skin involvement.

REFERENCES:

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.3161

POS0874
CLOT LYSIS TIME PREDICTS RECURRENT DIGITAL ULCERS IN SYSTEMIC SCLEROSIS AFTER ONE YEAR OF FOLLOW-UP: A NESTED CASE-CONTROL STUDY
J. Colic1, A. Antovic2, J. Vojinovic3, I. Pruner3, J. Vojinovic4, N. Damjanov5, M. Sefik Bukilica6,7
1Institute of Rheumatology, Department of Rheumatology IVb Unit, Belgrade, Serbia; 2Karolinska Institutet, Karolinska University Hospital Solna, Department of Medicine, Rheumatology Unit, Stockholm, Sweden; 3Karolinska Institute, Department of Molecular Medicine and Surgery, Stockholm, Sweden; 4Medical Faculty, University of Niš, Department of Pediatrics, Niš, Serbia; 5School of Medicine, University of Belgrade, Internal Medicine, Belgrade, Serbia; 6Institute of Rheumatology, Department of Rheumatology Unit, Belgrade, Serbia

Background: Digital ulcers (DU) are a common visible manifestation of vasculopathy in systemic sclerosis (SSc), which could be recurrent and associated with disability and mortality (1). Although vasculopathy is connected with impaired coagulation/fibrinolysis parameters and aberration of adhesion molecules, there are few data about their role in developing recurrent DU.

Objectives: To evaluate the possible role of Fibrin generation/Fibrinolysis parameters and adhesion molecules in the prediction of new ischaemic DU onset during a 1-year follow-up and their impact on the time to new DU onset (TD).

Methods: From 58 consecutive patients with SSc who fulfilled the 2013 ACR/EULAR SSc criteria and have never been treated with endothelin receptor antagonist, phosphodiesterase 5 inhibitors or prostanoids, a total of 38 patients with ever had DU, either active at inclusion or in past, were enrolled in a prospective cohort study. Each patient was given a “DU diary”; Demographic, clinical and serological data were recorded. The serum concentration of ICA1 and E-selectin were measured by ELISA. Haemostatic potential parameters: overall haemostasis (OHP), overall coagulation (OCP) and overall fibrinolysis (OFP) potential were assessed. Maximum absorbance (Cmax), reflects the fibrin clot density and clot lysis time (Lys50t0, time from initiation of clot formation to the time at which a 50% fall in absorbance from Cmax in the lysis assay), reflects fibrinolytic susceptibility, were calculated (2). Fibrin structure was visualised using scanning electron microscopy (SEM).

Results: Over the follow-up period, 18 patients (45.5%) developed new DU with the average TD of 7.4±2.9 months. There was no difference in ASA and CCB treatment among two groups (p>0.05). The OFP value was significantly decreased (p<0.01), Lys50t0 prolonged (p<0.05), while OHP was increased (p<0.05) in patients experienced new DU. Lys50t0 showed good validity in identifying patients with new DU onset (AUC 0.683 95% CI 0.5 - 0.9). By multivariate analysis including clinical data in model the Lys50t0 (HR 1.2, 95% CI 1.1-1.3, p=0.018) and active DU at enrollment (HR 9.6, 95% CI 1.4-66.8, p=0.022) were identified as independent risk factors for the occurrence of new DU. TD was inversely correlated with ICA1 (p<0.001), E selectin (p<0.05), Cmax (p<0.05) and Lys50t0 (p<0.001). Model explaining 81.6% of the TD variability included Lys50t0 (β=-0.55, p<0.003), E selectin (β=-0.44, p=0.014) and fibrinogen (β=0.49, p=0.017). SEM revealed denser fibrin clots with thinner fibres in group expereiced new DU compared to clots formed in plasma of patient without DU.

Conclusion: Our results provide evidence that impaired fibrinolysis has critical role in the progression of microvascular disease, identifying clot lysis time as a strong predictor in the onset of new digital ulcers in Systemic sclerosis. The higher level of E selectin and the longer lysis time are, the shorter is time until the onset of new digital ulcer. These results could be used in selection of patients at high risk of developing recurrent digital ulcer and therefore allow earlier therapeutic intervention.

REFERENCES:

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.3163

POS0875
MYOSITIS-SPECIFIC ANTIBODIES IN A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY
J. Álvarez Troncoso1, S. Carrasco Molina1, J. Valdivieso2, P. Nozaí2, A. Robles Marhuenda1, E. Martínez Robles3, C. Soto Abadnades4, J. J. Rios3, A. Noblezas Mozo1, F. Arnaich Fernández1, E. Hospital Universitario La Paz, Internal Medicine, Madrid, Spain; 2Hospital Universitario La Paz, Clinical Immunology, Madrid, Spain

Background: Myositis-specific antibodies (MSA) are highly specific and useful to classify patients as having syndromes with distinct clinical features and prognosis. MSA are almost always mutually exclusive and quite specific, adding value as a useful biomarker for diagnosis. Although individual autoantibodies aren’t sensitive enough to detect the full spectrum of idiopathic inflammatory myopathies (IIM), the sensitivity of a myositis panel is increasing as more autoantibodies are discovered, and as better assays become available.

Objectives: We aimed to analyze the usefulness of a myositis-specific immuno blot for the diagnosis of IIM in a hospital cohort from January 2019 to December 2020. We also seek to correlate immunological findings with the risk of associated interstitial lung disease (ILD), cancer, or death.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.2324
Sarcopenia is a frequent, progressive and generalized muscle disorder characterized by low muscle strength and mass leading to handicap, decreased quality of life and increased mortality. Prevalence and significance of sarcopenia in myositis patients has never been reported.

**Objectives:** To study sarcopenia in myositis patients with low or no disease activity.

**Methods:** Adult myositis patients (2017 ACR/EULAR criteria), with disease duration greater than 12 months, creatine kinase serum level (CK) less than 500 U/I, stable medication for 6 months were enrolled. Patients with inclusion body myositis were excluded. Total (LM) and appendicular (ALM) muscle mass were measured using dual-energy X-ray absorptiometry (DXA). Hologic and muscle grip strength was measured using Jamar dynamometer. Sarcopenia was defined according to the EWGSOP2 consensus.

**Results:** 29 patients (20 female, 68.9%), with a median age of 61 years (50.5-71) were enrolled. They suffered from dermatomyositis (DM, n=4), immune-mediated necrotizing myopathy (IMNM, n=8), anti-synthetase syndrome (ASS, n=9), scleromyositis (SM, n=8) since 4.7 years (2.8-8.3). At the evaluation, muscle strength assessed with MMT-8 was 139/150 (136-147), MMT-12 was 210/220 (204-216) and CK were 1315 UI (105.5-202). Four patients (13.8%) were sarcopenic. Sarcopenic patients were older (73.4 years (66.2-80.5) vs 58.7 years (44.2-79.6), p=0.03), with a longer disease duration (7.3 years (5.3-11.8) vs 4.3 (2.7-8.3), p=0.01), longer time with increased CK (449 days (169.8-954) vs 255.5 (124-872.8), higher maximum CK values (6000 UI (2205-7000) vs 1636 (900-4451)). They suffered from IMNM (2/4, 50%); DM (n=1) and SM (n=1) had more frequently disease-related cardiac involvement (50% vs 4%, p=0.04), and tended to a longer steroid therapy duration (2.4 years (0.8-5) vs 1.8 (1.3-3.9), p=0.09) and a higher number of immunomodulatory drugs (2.5 (2.5-3) vs 2 (2-3), p=0.03).

At the evaluation, sarcopenic patients were globally weaker as highlighted by lower MMT-12 (201 (196-206.8) vs 213 (207-217), p=0.02). Head flexor-extensors and proximal upper muscles were especially weaker (respectively, p=0.04 and p=0.03). Muscle performance was also lower in sarcopenic patients as assessed by distance covered at 6-minute walk test (6mtWT, p=0.003) and number of squats in 30 seconds (p=0.005). Time to drink a glass of water was significantly longer in sarcopenics (p=0.04) even if any patient referred dysphagia. Health assessment questionnaire score was greater (1.4 (0.8-2) vs 0.6 (0.2-1), p=0.04) indicating higher handicap. LM positively correlated with MMT-8 and MMT-12 (ρ = 0.7, p=0.0003) and 6mWT distance covered/lower limit (ρ = 0.5, p=0.01). Moreover, LM negatively correlated with time to drink a glass of water (p=0.06, p=0.002). Conclusion: Muscle mass measured by DXA is a relevant parameter for muscle damage and disability in myositis patients. Sarcopenic myositis patients represent a subgroup with important muscle damage and handicap.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2021-eular.3248

**POS0877**

**THE EFFECT OF PLATELET INHIBITORS ON DIGITAL ULCERS IN SYSTEMIC SCLEROSIS - A DERIVATION AND VALIDATION EUSTAR STUDY**

A. Garipan1, K. Steigmiller2, C. Gebhardt3, C. Mihal3, R. Dobrota1, M. Matucci-Cerinic1, J. Henes3, J. De Vries-Brouwer1, V. Smith1, A. Doria1, A. Allarone2, L. Dagna3, B. Anc1, C. Montecucco12, H. Kwai-Bielecka12, M. Martin14, Y. Tanaka15, A. M. Hoffmann-Vold1, U. Held1, O. Dister1, M. O. Becker1.

1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; 2Department of Biostatistics, at Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland; 3Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland; 4Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Sclerodema Unit, AOUC, Florence, Italy; 5Centre for Interdisciplinary Clinical Immunology, Rheumatology and Autoinflammatory Diseases and Department of Internal Medicine II (Hematology, Oncology, Immunology and Infectious Diseases), University Hospital Tübingen, Germany; 6Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands; 7Department of Internal Medicine, Ghent University Hospital, Belgium; 8Department of Rheumatology, Ghent University Hospital, Belgium; 9Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium; 10Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy; 11Department of Rheumatology A Descartes University, APHP Cochin Hospital, Paris, France; 12Unit of Immunology, Rheumatology,